Therapeutic Advances in Medical Oncology最新文献

{"title":"Patterns of lymph node metastasis in 441 patients with sinonasal squamous cell carcinoma.","authors":"Li Wang, Jie Wang, Tian Wang, Yi Li, Xinmao Song","doi":"10.1177/17588359241299331","DOIUrl":"10.1177/17588359241299331","url":null,"abstract":"<p><strong>Background: </strong>Due to the rarity of sinonasal squamous cell carcinoma (SNSCC), the distribution patterns of lymph node metastasis (LNM), the relationship between LNM and prognosis, and the optimal treatment of LNM lack sufficient evidence-based support.</p><p><strong>Objectives: </strong>To investigate the patterns of LNM in SNSCC and evaluate the impact of LNM on prognosis.</p><p><strong>Design: </strong>This was a retrospective cohort study.</p><p><strong>Methods: </strong>The medical records of 441 patients with SNSCC between 2009 and 2022 in one institution were retrospectively reviewed. We assessed the incidence, the distribution of LNM, and the relationship between LNM and long-term survival.</p><p><strong>Results: </strong>Seventy-three out of 441 patients (16.6%) presented LNM initially. Among the 73 patients, 34 patients (46.6%) had LNM in the region of ipsilateral level II; 22 patients (30.1%) had positive retropharyngeal lymph nodes; 20 patients (27.4%) had LNM in the region of ipsilateral level Ib; and nine patients (12.3%) had evidence of parotid LNM. Poor differentiation (<i>p</i> = 0.001), nasal cavity (<i>p</i> = 0.018), skin involvement (<i>p</i> = 0.036), and nasopharynx involvement (<i>p</i> = 0.009) were the risk factors for LNM. In the univariate and multivariate analyses, the overall survival (<i>p</i> = 0.25), progression-free survival (<i>p</i> = 0.22), regional failure-free survival (<i>p</i> = 0.20), and distant metastasis-free survival (<i>p</i> = 0.14) rates were not significantly decreased by the LNM. After the propensity score matching, LNM was still not correlated with poor long-term survival.</p><p><strong>Conclusions: </strong>The incidence of retropharyngeal and parotid LNM was higher than in previous studies. At initial diagnosis, the risk factors for LNM were identified, and LNM was not associated with poor survival outcomes.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"16 ","pages":"17588359241299331"},"PeriodicalIF":4.3,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11569498/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of repeat transurethral resection in no-muscle-invasive bladder tumour: an umbrella review.","authors":"Qing-Xin Yu, Rui-Cheng Wu, Zhou-Ting Tuo, Wei-Zhen Zhu, Jie Wang, Xing Ye, Koo Han Yoo, Wu-Ran Wei, De-Chao Feng, Deng-Xiong Li","doi":"10.1177/17588359241298470","DOIUrl":"10.1177/17588359241298470","url":null,"abstract":"<p><strong>Background: </strong>Repeat transurethral resection of bladder tumour (reTURB) is a conventional treatment for non-muscle-invasive bladder cancer (NMIBC) to enhance prognosis. However, the necessity of reTURB in NMIBC remains controversial owing to upstaging of treatments and new evidence.</p><p><strong>Objectives: </strong>We performed an umbrella review to determine the need for reTURB in patients with NMIBC.</p><p><strong>Design: </strong>We extracted data from meta-analyses that were screened out after a systematic search of PubMed, Embase, the Web of Science and the Cochrane Database of Systematic Reviews.</p><p><strong>Methods: </strong>Risk of Bias in Systematic Reviews and the Grading of Recommendations, Assessment, Development and Evaluation tools were used to assess the quality of each included meta-analysis and outcomes.</p><p><strong>Results: </strong>Our study included seven meta-analyses. Two studies assessed the efficiency of reTURB in patients who underwent en bloc resection of bladder tumours (ERBT). Patients who underwent ERBT reported low residual tumour and upstaging rates of 5.9% and 0.3%, respectively. Conversely, patients who underwent conventional transurethral resection for bladder cancer (cTURB) had high residual tumour rates. Patients who underwent cTURB and reTURB had significantly improved 1-year recurrence-free survival (RFS) compared to those who underwent initial cTURB alone. In terms of progression-free survival (PFS), a meta-analysis reported that patients who underwent cTURB and reTURB had significantly improved PFS compared with those who underwent initial cTURB alone. In the subgroup analyses of ERBT, reTURB did not affect the RFS and PFS of patients who received ERBT. Currently, only a limited number of randomised clinical trials have evaluated reTURB, and various factors have influenced its efficacy.</p><p><strong>Conclusion: </strong>There was significant variation in survival outcomes among patients undergoing reTURB. The necessity and efficacy of reTURB depend on numerous factors, such as surgical approach, equipment and medication usage. Patients eligible for ERBT may constitute a group that does not require reTURB. Further clinical trials are required to validate these findings.</p><p><strong>Registration: </strong>This umbrella review was registered with the International Prospective Register of Systematic Reviews (CRD42023439078).</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"16 ","pages":"17588359241298470"},"PeriodicalIF":4.3,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11569495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report: successful treatment of primary intradural extramedullary extraskeletal Ewing sarcoma in adult patient with intralesional surgery, chemotherapy, and proton beam therapy of the cerebrospinal axis.","authors":"Mateusz Ziomek, Joanna Placzke, Konrad Urbanek, Tomasz Skóra, Piotr Rutkowski, Mateusz Jacek Spałek","doi":"10.1177/17588359241297868","DOIUrl":"10.1177/17588359241297868","url":null,"abstract":"<p><p>Ewing sarcoma is a rare malignant neoplasm that primarily affects bone in children. Extraskeletal location is less common, while intradural extramedullary Ewing sarcoma (IEES) in adults is a casuistic phenomenon. Due to its rarity, a standardized treatment strategy for IEES has not been established. The clinical use of proton beam therapy (PBT) for craniospinal irradiation (CSI) in the treatment of IEES has not been reported in the literature. A 41-year-old previously healthy man presented with disabling gluteal and lower extremity pain, decreased sensation, and progressive paraparesis without sphincter dysfunction. Imaging showed intradural extramedullary spinal lesions. The patient underwent urgent surgery. Histology and immunohistochemistry suggested a poorly differentiated neuroendocrine tumor. Negative chromogranin staining and a high Ki67 index prompted further investigation. Next-generation sequencing later confirmed an <i>EWSR1/FLI1</i> translocation, leading to the diagnosis of extraskeletal Ewing sarcoma. The patient received standardized chemotherapy with marked clinical improvement. PBT CSI was initiated but was interrupted due to COVID-19 and other complications. At 20 months follow-up, no recurrence was observed, and the patient reported an active life. Despite intra-spinal spread and multiple complications, intensive chemotherapy combined with PBT CSI led to a favorable outcome. CSI rather than focal radiotherapy should be considered for patients with IEES limited to the cerebrospinal axis. PBT may be used as an alternative to photon radiotherapy to better spare organs at risk.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"16 ","pages":"17588359241297868"},"PeriodicalIF":4.3,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11569501/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world overall survival in second-line maintenance niraparib monotherapy versus active surveillance in patients with <i>BRCA</i> wild-type recurrent ovarian cancer.","authors":"Robert L Coleman, Jessica A Perhanidis, Linda Kalilani, Nicole M Zimmerman, Amanda Golembesky, Kathleen N Moore","doi":"10.1177/17588359241292272","DOIUrl":"10.1177/17588359241292272","url":null,"abstract":"<p><strong>Background: </strong>The NOVA study (NCT01847274) compared niraparib with placebo as a maintenance treatment for patients with recurrent ovarian cancer (OC) but was not powered to detect an overall survival (OS) improvement.</p><p><strong>Objective: </strong>To compare OS in a real-world population of patients with <i>BRCA</i> wild-type (<i>BRCA</i>wt) recurrent OC who received second-line maintenance (2LM) niraparib monotherapy versus active surveillance (AS).</p><p><strong>Design: </strong>A retrospective study using a US-based nationwide deidentified electronic health record-derived database.</p><p><strong>Methods: </strong>Patients diagnosed with epithelial OC (January 1, 2011-May 31, 2021) who completed second-line (2L) therapy (January 1, 2017-March 2, 2022) and were <i>BRCA</i>wt were included. A NOVA study-like subpopulation included patients with an Eastern Cooperative Oncology Group performance status score of 0-1 and platinum-sensitive disease. Patients were assigned to 2LM niraparib or AS cohorts. Follow-up was measured from the index date (2L non-maintenance therapy end) until the first of study end (May 31, 2022), last clinical activity, or death. Median OS (mOS) and hazard ratios were estimated with an emulated trial methodology.</p><p><strong>Results: </strong>The overall population comprised 199 patients in the 2LM niraparib monotherapy cohort and 707 patients in the AS cohort; the NOVA study-like subpopulation included 123 patients in the 2LM niraparib monotherapy cohort and 143 in the AS cohort. Demographic and clinical characteristics were similar in both populations. Overall, adjusted mOS was 24.1 months for the 2LM niraparib monotherapy cohort versus 18.4 months for the AS cohort (hazard ratio, 0.8; 95% confidence interval [CI]: 0.7-0.9). In the NOVA study-like subpopulation, adjusted mOS was 28.1 months for the 2LM niraparib monotherapy cohort versus 21.5 months for the AS cohort (hazard ratio, 0.6; 95% CI: 0.5-0.9).</p><p><strong>Conclusion: </strong>These results provide important real-world OS data for patients with recurrent <i>BRCA</i>wt OC who received niraparib monotherapy compared with patients receiving AS.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"16 ","pages":"17588359241292272"},"PeriodicalIF":4.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11565610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elacestrant plus alpelisib in an <i>ESR1</i> and <i>PIK3CA</i> co-mutated and heavily pretreated metastatic breast cancer: the first case report for combination efficacy and safety.","authors":"Ünal Metin Tokat, Şevval Nur Bilgiç, Esranur Aydın, Ashkan Adibi, Eylül Özgü, Onur Tutar, Mutlu Demiray","doi":"10.1177/17588359241297101","DOIUrl":"10.1177/17588359241297101","url":null,"abstract":"<p><p>Breast cancer (BC) is the leading cause of cancer-related mortality among women, and hormone receptor (HR)-positive subtype makes up the majority of all cases. The standard of care in HR⁺/HER2^- metastatic BC (MBC) is endocrine therapy (ET) plus a CDK4/6 inhibitor (CDK4/6i). <i>ESR1</i> mutations could impair the clinical efficacy of the ETs. Similarly, <i>PIK3CA</i> mutations may serve as a negative prognostic marker. Furthermore, MBC is challenging to treat despite new drug approvals. Our patient received multiple lines of ET ± CDK4/6i and chemotherapy but persistently progressed after each or stopped the treatment due to adverse events. Here we showed for the first time that an all-oral combination of elacestrant plus alpelisib was feasible, tolerable, and clinically active in an <i>ESR1</i> and <i>PIK3CA</i> co-mutated and heavily pretreated patient. We achieved a remarkable response in the metastatic lesions with minor toxicity issues. This case highlights the importance of utilizing up-to-date therapeutic agents and reactive decision-making during personalized cancer treatment.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"16 ","pages":"17588359241297101"},"PeriodicalIF":4.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142628523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of antibody drug conjugates in the treatment of patients with breast cancer brain metastases.","authors":"Stacey Pan, Jayant Y Gadrey, Sarah Sammons, Nancy U Lin, Sara M Tolaney, Paolo Tarantino, Ilana Schlam","doi":"10.1177/17588359241292266","DOIUrl":"https://doi.org/10.1177/17588359241292266","url":null,"abstract":"<p><p>Breast cancer remains a leading cause of brain metastases (BM), which carry a poor prognosis. The current approach to managing BMs in breast cancer patients involves a combination of local therapies (surgery, radiotherapy) and systemic treatments. Developing newer antibody-drug conjugates (ADCs) has sparked a revolution in metastatic breast cancer (MBC) care. ADCs such as ado-trastuzumab emtansine, trastuzumab deruxtecan, and sacituzumab govitecan have demonstrated significant improvement in patient outcomes and are standard of care in the treatment of MBC. Most of the ADC registration studies included patients with stable BMs but excluded individuals with active BM, making intracranial (IC) response assessment a challenge. Promising data has recently emerged, suggesting relevant IC activity for certain ADCs and ongoing studies in patients with active BM that will expand our knowledge. This review aims to summarize the effectiveness of approved ADCs as well as promising new ADCs in development for breast cancer with BM.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"16 ","pages":"17588359241292266"},"PeriodicalIF":4.3,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142628530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-minimization analysis comparing subcutaneous trastuzumab at home with intravenous trastuzumab for HER2-positive breast cancer in Singapore.","authors":"Yanting Ouyang, Han Yi Lee, Fun Loon Leong, Han Jieh Tey, Vivianne Shih, Elaine Hsuen Lim, Nicholas Graves","doi":"10.1177/17588359241293381","DOIUrl":"https://doi.org/10.1177/17588359241293381","url":null,"abstract":"<p><strong>Background: </strong>Trastuzumab (Herceptin) can be administered intravenously (IV Herceptin) and subcutaneously, with similar efficacy and safety, but with differences in dosage and costs. Previous studies have evaluated the costs of both treatment approaches in the outpatient settings, but no study has compared the costs of IV Herceptin administered in outpatients with subcutaneous Herceptin administered at patients' homes (Homecare SC Herceptin).</p><p><strong>Objectives: </strong>This study aimed to compare the per-patient costs of Homecare SC Herceptin versus IV Herceptin administered in a healthcare institution's outpatient setting in Singapore.</p><p><strong>Designs: </strong>We performed a model-based cost-minimization analysis to estimate and compare the per-patient annual costs associated with each treatment modality from a societal perspective.</p><p><strong>Methods: </strong>Direct cost comprised healthcare resources utilization: drug, consumables, manpower, facility and cardiac assessment. Indirect cost was valued using a human capital approach to account for productivity lost by patients. Monte Carlo simulations with 1000 iterations were performed to account for parameter uncertainties. Costs were reported in 2023 Singapore dollars.</p><p><strong>Results: </strong>The annual societal cost per patient receiving IV Herceptin ranged from S$64,194 to S$65,135, while for Homecare SC Herceptin, it ranged from S$25,865 to S$26,807. Homecare SC Herceptin reduced the annual cost burden by 58.8% and 59.7%, per non-metastatic and metastatic breast cancer patient, respectively. The primary cost contributor was drug therapy, comprising more than 90% of the total cost. Even when excluding the cost of drugs, Homecare SC Herceptin remained cheaper by S$1912 annually. The cost reduction is approximately 60% compared to IV Herceptin regardless of disease status, with a 100% probability that the decision to adopt Homecare SC Herceptin leads to cost savings in Singapore.</p><p><strong>Conclusion: </strong>Treatment of breast cancer with Homecare SC Herceptin is a cost-saving option compared to IV Herceptin.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"16 ","pages":"17588359241293381"},"PeriodicalIF":4.3,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552043/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142628229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-hypertensives associated with survival in cancer patients receiving immunotherapy: new evidence from a real-world cohort study and meta-analysis.","authors":"Ping Ma, Zhihuan Zhang, Mengying Qian, Hao Jiang, Yu Zhao, Qing Shan, Xia Liu, Tianming Yao, Jinmin Guo","doi":"10.1177/17588359241292227","DOIUrl":"https://doi.org/10.1177/17588359241292227","url":null,"abstract":"<p><strong>Background: </strong>The efficacy of immune checkpoint inhibitors (ICIs) in cancer patients taking anti-hypertensive drugs is still not well established.</p><p><strong>Objective: </strong>To elucidate the effect of anti-hypertensive drugs on the clinical outcome of cancer patients receiving immunotherapy.</p><p><strong>Design: </strong>A retrospective cohort study and meta-analysis.</p><p><strong>Method: </strong>We conducted a real-world retrospective study of cancer patients treated with immunotherapy at two tertiary centers between January 2019 and June 2023, with primary outcomes being overall survival (OS) and progression-free survival (PFS). In addition, we performed a meta-analysis to synthesize currently relevant clinical studies.</p><p><strong>Results: </strong>A retrospective clinical study of 336 patients from 2 centers suggested that the use of anti-hypertensive drugs was related to a preferable OS (hazard ratio (HR) = 0.55, 95% confidence interval (CI): 0.33-0.90) compared to non-users. For PFS, no significant correlation was detected (HR = 0.71, 95% CI: 0.49-1.03). Further analysis revealed that renin-angiotensin system inhibitor (RASi) and calcium channel blocker (CCB) have a synergistic effect with ICIs. In addition, subgroup analysis found that the benefits of RASi or CCB in combination with ICIs are greater in women or patients ⩾65 years of age. There was better disease control in lung cancer patients using RASi, and a significantly longer OS was observed in patients with gastrointestinal tumors taking CCB. Meta-analysis suggested that anti-hypertensive drugs were associated with improved OS, but only the combination of RASi and immunotherapy showed a synergistic effect. No significant correlation with OS was found for other anti-hypertensive drugs, and there was no overall positive effect on PFS.</p><p><strong>Conclusion: </strong>Our study found that use of anti-hypertensive drugs, particularly RASi or CCB, was associated with improved OS in patients undergoing immunotherapy. The synergistic effects of RASi or CCB with ICIs were more pronounced in females or elderly. RASi or CCB exhibited different benefits in various types of tumors. These findings provide valuable insights for treating cancer patients with hypertension.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"16 ","pages":"17588359241292227"},"PeriodicalIF":4.3,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142628047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapy-relevant <i>MDM2</i> amplification in cholangiocarcinomas in Caucasian patients.","authors":"Su Ir Lyu, Patrick Sven Plum, Caroline Fretter, Adrian Georg Simon, Tillmann Bedau, Karl Knipper, Michael N Thomas, Dirk Stippel, Britta Janina Wagner, Christiane Bruns, Dirk Waldschmidt, Reinhard Büttner, Uta Drebber, Alexander Quaas","doi":"10.1177/17588359241288123","DOIUrl":"https://doi.org/10.1177/17588359241288123","url":null,"abstract":"<p><strong>Background: </strong>Cholangiocarcinomas (CCA) are a group of aggressive malignancies with poor prognosis. The distinct subtypes are related to different etiologies and genetic aberrations that are subject to targeted therapies. Mouse double minute 2 homolog (MDM2) is a potent inhibitor of tumor suppressor p53 and is proven to be altered in certain carcinomas. Novel targeted drugs, such as the MDM2-p53 antagonist Brigimadlin, have shown promising results for therapeutic efficacy in patients with <i>MDM2</i> amplification and wild-type <i>TP53</i>.</p><p><strong>Objectives: </strong>This study therefore aimed to characterize CCAs regarding their MDM2 status, compare the concordance between fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) methods, and elucidate the role of <i>MDM2</i> amplification in prognosis and other clinicopathological characteristics.</p><p><strong>Design: </strong>Retrospective cohort study.</p><p><strong>Methods: </strong>All patients (<i>n</i> = 52) were diagnosed with CCA and received surgical resection with curative intention at the University Hospital of Cologne. Samples were analyzed retrospectively for <i>MDM2</i> amplification with FISH and IHC. We correlated results with pre-existing molecular as well as clinical data.</p><p><strong>Results: </strong>We included 52 patients with primary CCA, three of which showed positive <i>MDM2</i> amplification (5.8%). <i>MDM2</i> amplification was present only in the intrahepatic CCA type and all patients with positive <i>MDM2</i> amplification exhibited normal p53 status. Among the large-duct subtypes of intrahepatic CCAs, patients with positive <i>MDM2</i> amplification demonstrated better survival than patients with negative <i>MDM2</i> amplification (<i>p</i> = 0.041). Of the patients with MDM2 amplification, two underwent adjuvant therapy post-surgery (66.7%). There was a strong correlation between <i>MDM2</i> amplification and positive protein expression in IHC. There were no identifiable molecular co-alterations of <i>MDM2</i> with <i>FGFR2</i> or SWI/SNF complex alterations.</p><p><strong>Conclusion: </strong>Real-world evidence in our Caucasian patient population confirmed that a significant number of intrahepatic CCAs showcase <i>MDM2</i> amplification, qualifying for a personalized therapy option with Brigimadlin. <i>MDM2</i> amplification must therefore be considered in the context of personalized molecular testing in CCA.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"16 ","pages":"17588359241288123"},"PeriodicalIF":4.3,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11550496/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142628540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioinformatic and clinical experimental assay uncovers resistance and susceptibility mechanisms of human glioblastomas to temozolomide and identifies new combined and individual survival biomarkers outperforming <i>MGMT</i> promoter methylation.","authors":"Alexander Modestov, Marianna Zolotovskaia, Maria Suntsova, Galina Zakharova, Aleksander Seryakov, Ivana Jovcevska, Jernej Mlakar, Elena Poddubskaya, Aleksey Moisseev, Grigory Vykhodtsev, Sergey Roumiantsev, Maksim Sorokin, Victor Tkachev, Aleksander Simonov, Anton Buzdin","doi":"10.1177/17588359241292269","DOIUrl":"https://doi.org/10.1177/17588359241292269","url":null,"abstract":"<p><strong>Background: </strong>Glioblastoma (GBM) is the most aggressive and lethal central nervous system (CNS) tumor. The treatment strategy is mainly surgery and/or radiation therapy, both combined with adjuvant temozolomide (TMZ) chemotherapy. Historically, methylation of <i>MGMT</i> gene promoter is used as the major biomarker predicting individual tumor response to TMZ.</p><p><strong>Objectives: </strong>This research aimed to analyze genes and molecular pathways of DNA repair as biomarkers for sensitivity to TMZ treatment in GBM using updated The Cancer Genome Atlas (TCGA) data and validate the results on experimental datasets.</p><p><strong>Methods: </strong>Survival analysis of GBM patients under TMZ therapy and hazard ratio (HR) calculation were used to assess all putative biomarkers on World Health Organization CNS5 reclassified TCGA project collection of molecular profiles and experimental multicenter GBM patient cohort. Pathway activation levels were calculated for 38 DNA repair pathways. TMZ sensitivity pathway was reconstructed using a human interactome model built using pairwise interactions extracted from 51,672 human molecular pathways.</p><p><strong>Results: </strong>We found that expression/activation levels of seven and six emerging gene/pathway biomarkers served as high-quality positive (HR < 0.61) and negative (HR > 1.63), respectively, patient survival biomarkers performing better than <i>MGMT</i> methylation. Positive survival biomarkers were enriched in the processes of ATM-dependent checkpoint activation and cell cycle arrest whereas negative-in excision DNA repair. We also built and characterized gene pathways which were informative for GBM patient survival following TMZ administration (HR 0.18-0.44, <i>p</i> < 0.0009; area under the curve 0.68-0.9).</p><p><strong>Conclusion: </strong>In this study, a comprehensive analysis of the expression of 361 DNA repair genes and activation levels of 38 DNA repair pathways revealed 13 potential survival biomarkers with increased prognostic potential compared to <i>MGMT</i> methylation. We algorithmically reconstructed the TMZ sensitivity pathway with strong predictive capacity in GBM.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"16 ","pages":"17588359241292269"},"PeriodicalIF":4.3,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11544758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142628222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}